107 -10 (60) 2023 — Nurullaeva D.F., Mukhamedjanova M.Kh. — CHARACTERISTICS OF HEMATOLOGICAL CHANGES IN PATIENTS WITH CHRONIC HCV INFECTION AND WAYS OF THEIR CORRECTION

CHARACTERISTICS OF HEMATOLOGICAL CHANGES IN PATIENTS WITH CHRONIC HCV INFECTION AND WAYS OF THEIR CORRECTION

Nurullaeva D.F., Bukhara State Medical Institute named after Abu Ali ibn Sina

Mukhamedjanova M.Kh. Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Objective – to characterize changes in the blood system that occur during antiviral therapy for chronic hepatitis C (HCV) and modern methods for their correction. The presented scientific review provides information about the main hematological side effects and methods for their correction in modern antiviral therapy for chronic HCV infection.

Key words: chronic HCV infection, anemia, antiviral therapy.

First page

639

Last page

641

For citation: Nurullaeva D.F., Mukhamedjanova M.Kh. – CHARACTERISTICS OF HEMATOLOGICAL CHANGES IN PATIENTS WITH CHRONIC HCV INFECTION AND WAYS OF THEIR CORRECTION //New Day in Medicine 2023 10(60): 639-641 https://newdaymedicine.com/index.php/2023/12/17/l-626/

LIST OF REFERENCES:

1. Лобзин Ю.В., Крюков Е.В., Жданов К.В. и др. Система выявления и медицинского сопровождения при HBV- и HCV-инфекциях у военнослужащих по призыву (на модели Черноморского флота) // Гепатология. 2003;1:6-10.
2. Lavanchy D. Evolving epidemiology of hepatitis C virus. // Clin. Microbiol. Infect. 2011;17(2):107-115.
3. Гармаева Т.Ц. Вирусные гепатиты В и С у больных заболеваниями системы крови: автореф. дис. д-ра мед. наук. М., 2012.
4. Fried M.W. Side effects of therapy of hepatitis C and their management // Hepatology. 2002;36(5):237-244.
5. Rossotti R., Travi G., Pazzi A. et al. Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report // J. Hepatol. 2015;62(1):234-237.
6. Carrier P., Jaccard A., Jacques J. et al. HCV-associated B-cell non- Hodgkin lymphomas and new direct antiviral agents // Liver Int. 2015;35(10):2222-2227.
7. Peveling-Oberhag J., Arcaini L., Bankov K. et al. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis // J. Viral Hepat. 2016;23(7):536-544.
8. Sulkowski M.S., Wasserman R., Brooks L. et al. Changes in haemo- globin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection // J. Viral Hepat. 2004;11(3):243-250.
9. Jacobson I.M., McHutchison J.G., Dusheiko G. et al. Telaprevir for previously untreated chronic hepatitis C virus infection // N. Engl. J. Med. 2011;364(25):2405-2416.
10. Mukhamedjanova MH Anemia in patients with interferences and interpretation of modern therapy. NDM 2021;4(36):150-152.
11. M.Kh. Mukhamedzhanova, N.Sh. Ahmedova. Determination of hepsidin in patients with chronic hepatitis associated with chf as a predictor of the severity of hepatocardial syndrome. // Art of Medicine International Medical Scientific Journal 10.5281/zenodo.7361300 Vol 2, Issue 3 P.332-336.
12. Soota K., Maliakkal B. Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection // World J. Gastroenterol. 2014;20(43):184-190.
13. Dieterich D.T., Spivak, J.L. Hematologic disorders associated with hepatitis C virus infection and their management // Clin. Infect. Dis. 2003;37(4):533-541.
14. Милованова С.Ю., Козловская Л.В., Лопаткина Т.Н. Анемии при острых и хронических заболеваниях печени. клиническая гепатология. 2006;2(2):16-23.
15. Соловьева А.Е. и др. Прогностическое значение плотности печени при декомпенсированной сердечной недостаточности: результаты проспективного обсервационного исследования на основе данных непрямой эластометрии / А.Е. Соловьева, Ж.Д. Кобалава, С.В. Виллевальде, М. Баярсайхан, И.В. Гармаш, М. Фудим // Кардиология. – 2018;58(10):20-32.